Trade

with

Zogenix Inc
(NASDAQ: ZGNX)
AdChoices
1.38
+0.05
+3.76%
After Hours :
1.38
0.00
0.00%

Open

1.33

Previous Close

1.33

Volume (Avg)

1.79M (1.77M)

Day's Range

1.32-1.39

52Wk Range

1.07-5.19

Market Cap.

194.64M

Dividend Rate ( Yield )

-

Beta

1.27

Shares Outstanding

141.04M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 33.01M

    • Net Income

    • -80.86M

    • Market Cap.

    • 194.64M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -13.37

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.27

    • Forward P/E

    • -3.73

    • Price/Sales

    • 5.27

    • Price/Book Value

    • 2.85

    • Price/Cash flow

    • -2.55

      • EBITDA

      • -72.44M

      • Return on Capital %

      • -4.86

      • Return on Equity %

      • -17.36

      • Return on Assets %

      • -4.86

      • Book Value/Share

      • 0.48

      • Shares Outstanding

      • 141.04M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 2.50

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.42

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 2.40

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 40.10

            • 69.92

            • Pre-Tax Margin

            • -13.37

            • 21.84

            • Net Profit Margin

            • -13.37

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.03

              • 0.32

              • Current Ratio

              • 2.13

              • 1.92

              • Quick Ratio

              • 1.59

              • 1.31

              • Interest Coverage

              • 0.28

              • 17.64

              • Leverage Ratio

              • 1.95

              • 2.03

              • Book Value/Share

              • 0.48

              • 14.72

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -33.90

                • 21.74

                • P/E Ratio 5-Year High

                • -194.74

                • 193.96

                • P/E Ratio 5-Year Low

                • -30.20

                • 87.26

                • Price/Sales Ratio

                • 4.58

                • 3.68

                • Price/Book Value

                • 2.48

                • 3.66

                • Price/Cash Flow Ratio

                • -2.55

                • 13.76

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -17.36

                    (-)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • -4.86

                    (-79.80)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • 4.29

                    (-)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • -

                  • 90.07k

                  • Inventory Turnover

                  • 1.41

                  • 2.46

                  • Asset Turnover

                  • 0.36

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -53.19M
                  Operating Margin
                  -161.13
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.55
                  Ownership

                  Institutional Ownership

                  85.66%

                  Top 10 Institutions

                  73.46%

                  Mutual Fund Ownership

                  35.68%

                  Float

                  69.17%

                  5% / Insider Ownership

                  2.37%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Kaufmann Fund

                  •  

                    18,710,000

                  • 0.00

                  • 13.27

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    9,804,706

                  • 0.00

                  • 6.95

                  • AST Federated Aggressive Growth

                  •  

                    3,080,000

                  • 0.00

                  • 2.18

                  • Federated Kaufmann Small Cap Fund

                  •  

                    2,868,000

                  • -1.61

                  • 2.03

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,949,168

                  • 4.46

                  • 1.38

                  • iShares Russell 2000 (AU)

                  •  

                    1,910,970

                  • -1.01

                  • 1.57

                  • iShares Nasdaq Biotechnology

                  •  

                    1,885,272

                  • 3.08

                  • 1.55

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    1,284,991

                  • 0.00

                  • 0.91

                  • Vanguard Extended Market Index Fund

                  •  

                    1,168,928

                  • 0.00

                  • 0.83

                  • iShares Russell 2000 Growth

                  •  

                    884,772

                  • 0.77

                  • 0.73

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Global Inv Mgmt Corp

                  •  

                    25,064,700

                  • +698.24%

                  • 17.77

                  • Fidelity Management and Research Company

                  •  

                    11,089,697

                  • 0.00%

                  • 7.86

                  • Gilder Gagnon Howe & CO LLC

                  •  

                    9,094,107

                  • -25.45%

                  • 6.45

                  • Visium Asset Management LLC

                  •  

                    5,413,000

                  • -1.58%

                  • 3.84

                  • Broadfin Capital, LLC

                  •  

                    5,137,645

                  • 0.00%

                  • 3.64

                  • BlackRock Fund Advisors

                  •  

                    4,652,316

                  • +4.17%

                  • 3.30

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Slow Growth

                  Style

                  Small Growth

                  Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and centr...moreal nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company’s first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous ...moredelivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company’s strategy is to commercialize and develop differentiated central nervous system and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products. The Company’s main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company completed Phase 3 development of Zohydro ER in 2011, and submitted an NDA for Zohydro ER to the FDA in May 2012. The FDA approved the NDA for Zohydro ER in October 2013 and the Company launched the product on March 3, 2014. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation’s SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.lessless

                  Key People

                  Roger L. Hawley

                  Director/CEO/Co-Founder

                  Cam L. Garner

                  Chairman of the Board/Director/Co-Founder

                  John J. Turanin

                  General Manager, Divisional/Vice President/Co-Founder

                  Steven J. Farr,PhD

                  Co-Founder/Director/President

                  Mr. Bret E. Megargel

                  Vice President, Divisional/Co-Founder

                  • Zogenix Inc

                  • 12400 High Bluff Drive

                  • San Diego, CA 92130

                  • USA.Map

                  • Phone: +1 858 259-1165

                  • Fax: +1 858 259-1166

                  • zogenix.com

                  Incorporated

                  2006

                  Employees

                  235

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: